ARTICLE | Product Development

Bringing precision medicine to obesity — without limiting market size

How real-time PK/PD monitoring could give the chasing pack an advantage in the GLP-1 market

March 4, 2024 4:55 AM UTC

With Novo Nordisk and Eli Lilly far and away the leaders in the nascent yet exploding obesity commercial market, one option for follow-on competitors to differentiate could be a precision medicine approach that provides either better tolerability, better efficacy, or ideally, both.

The first wave of GLP-1-based obesity therapies have broad labels, giving Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) and Eli Lilly and Co. (NYSE:LLY) little incentive to pursue a precision medicine strategy with the first-generation products. ...